Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Cytomegalovirus Infections 1

Interventions

fludarabine phosphate 6Whole-Body Irradiation 5Mycophenolic Acid 5Peripheral Blood Stem Cell Transplantation 4Cyclosporins 4Cyclosporine 4Cyclophosphamide 3Alemtuzumab 3fludarabine 2carmustine, poliferprosan 20 drug combination 2Stem Cell Transplantation 2Sirolimus 2Melphalan 2Etoposide 2Cytarabine 2Carmustine 2venetoclax 1thymoglobulin 1romidepsin 1niraparib 1nelarabine 1letermovir 1itacitinib 1ibrutinib 1Tacrolimus 1Mitoxantrone 1Interleukin-15 1INCB039110 1Hematopoietic Stem Cell Transplantation 1GRN163L peptide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Prolymphocytic, T-Cell × letermovir × Clear all
NCT04312841 2025-02-28

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
6 enrolled 11 charts
DermatologicLymphoidOther hematologic neoplasm

Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡